Fertility preservation immediately after therapeutic abortion results in multiple normal follicular growth with the absence of mature oocytes due to early luteinization: a case report and literature review. (2nd November 2021)

• Record Type: Journal Article
• Authors: Hamada, Haru; Hayama, Tomonari; Ijuin, Akifumi; Miyakoshi, Ai; Kasai, Michi; Tochihara, Shiori; Saito, Marina; Nishi, Mayuko; Ueno, Hiroe; Yamamoto, Mizuki; Komeya, Mitsuru; Yumura, Yasushi; Sakakibara, Hideya; Miyagi, Etsuko; Murase, Mariko
• Is Part Of: Gynecological endocrinology. Volume 37:Number 11(2021)
• Page Start: 1050
• Page End: 1053
• Publication Date: 2021-11-02
• Subjects: Acute leukemia -- fertility preservation -- cryopreservation -- post-abortion ovarian stimulation -- premature luteinization -- hCG level; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.1080/09513590.2021.1950135
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: Cancer therapy has priority over fertility preservation. The time available for fertility preservation in patients with cancer is often very limited and depends on the condition of the underlying disease. This case report presents the results of two rounds of controlled ovarian stimulations (COSs) performed after an induced abortion. The patient had mixed phenotype acute leukemia diagnosed during early pregnancy and underwent a surgical abortion, followed by ovarian stimulation using urinary follicle-stimulating hormone (uFSH) and gonadotropin-releasing hormone (GnRH) agonists. Oocyte retrieval was subsequently performed for oocyte cryopreservation. Despite good hormonal and ultrasonic follicular growth, no oocytes were obtained. During a second COS performed at a low human chorionic gonadotropin (hCG) level (less than 100 IU/L), several mature oocytes were obtained, suggesting that higher hCG levels during COS induce the absence of mature oocytes during normal follicular growth. It is recommended to start COS post-abortion after confirming a low hCG level while considering the timing of cancer treatment.